Thrombospondin repeat (TSR)-like domains are structures involved with cell adhesion. Plasmodium falciparum proteins containing TSR domains play crucial roles in parasite development. In particular, the preerythrocytic P. falciparum circumsporozoite protein is involved in hepatocyte invasion. The importance of these domains in two other malaria proteins, the merozoite-specific thrombospondin-related anonymous protein (MTRAP) and the thrombospondin-related apical membrane protein (PTRAMP), were assessed using near-full-length recombinant proteins composed of the extracellular domains produced in Escherichia coli. MTRAP is thought to be released from invasive organelles identified as micronemes during merozoite invasion to mediate motility and host cell invasion through an interaction with aldolase, an actin binding protein involved in the moving junction. PTRAMP function remains unknown. In this study, the conformation of recombinant MTRAP (rMTRAP) appeared to be a highly extended protein (2 nm by 33 nm, width by length, respectively), whereas rPTRAMP had a less extended structure. Using an erythrocyte binding assay, rMTRAP but not rPTRAMP bound human erythrocytes; rMTRAP binding was mediated through the TSR domain. MTRAP- and in general PTRAMP-specific antibodies failed to inhibit P. falciparum development in vitro. Altogether, MTRAP is a highly extended bifunctional protein that binds to an erythrocyte receptor and the merozoite motor.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3346429PMC
http://dx.doi.org/10.1128/EC.00039-12DOI Listing

Publication Analysis

Top Keywords

plasmodium falciparum
8
protein involved
8
highly extended
8
protein
6
mtrap
5
analysis conformation
4
conformation function
4
function plasmodium
4
falciparum
4
falciparum merozoite
4

Similar Publications

Purpose: Anopheles gambiae is a vector of Plasmodium falciparum and Wuchereria bancrofti. Endosymbionts are reported to block development of various parasites in mosquitoes. Microsporidia was reported to affect the development of P.

View Article and Find Full Text PDF

Malaria, a mosquito-borne disease caused by five plasmodium species, still has a life-threatening risk worldwide. Clinical manifestations can range from mild nonspecific symptoms to severe disease. In non-endemic regions, sporadic cases frequently pose significant challenges to health workers as delayed diagnosis can lead to serious consequences and even death.

View Article and Find Full Text PDF

Emoquine-1: A Hybrid Molecule Efficient against Multidrug-Resistant Parasites, Including the Artemisinin-Resistant Quiescent Stage, and Also Active In Vivo.

J Med Chem

January 2025

Laboratoire de Chimie de Coordination du CNRS, LCC-CNRS, Inserm ERL 1289 MAAP, Université de Toulouse, 205 route de Narbonne, 31077 Toulouse cedex, France.

To challenge the multidrug resistance of malaria parasites, new hybrid compounds were synthesized and evaluated against laboratory strains and multidrug-resistant clinical isolates. Among these hybrids, emoquine-1 was the most active on proliferative , with IC values in the range of 20-55 nM and a high selectivity index with respect to mammalian cells. This drug retained its activity on several multiresistant field isolates from Cambodia and Guiana, exhibited no cross-resistance to artemisinin, and is also very active against the quiescent stage of the artemisinin-resistant parasites, three features that constitute the gold standard for new antimalarial drugs.

View Article and Find Full Text PDF

Malaria is caused by protozoan parasites of the genus Plasmodium and remains a global health concern. The parasite has a highly adaptable life cycle comprising successive rounds of asexual replication in a vertebrate host and sexual maturation in the mosquito vector Anopheles. Genetic manipulation of the parasite has been instrumental for deciphering the function of Plasmodium genes.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!